Issues related to drug pricing, bona fide service fees, Affordable Care Act subsidies, pharmacies, provider status, biosimilars, cell and gene therapy, food is medicine; issues related to provider reimbursement, Medicare and Medicaid, workforce shortages, and product shortages (H.R.4299 Protecting Patient Access to Cancer and Complex Therapies Act; H.R.5031 Preserving Patient Access to Long-Term Care Pharmacies Act; H.R.3164/S.2426 Ensuring Community Access to Pharmacist Services Act). Issues related to DMEPOS supplies, competitive bidding, reimbursement to home health agencies, and acute hospital care at home services (H.R.5142 Home Health Stabilization Act of 2025; H.R. 4313 Hospital Inpatient Services Modernization Act).
Education on supply chain issues, drug shortages, domestic manufacturing, medical device environmental issues; Issues related to the medical supply chain and transportation.
Issues related to tariffs, trade, and U.S. trade policy.
Issues related to tariffs, trade, and U.S. trade policy.